[Hormone replacement therapy for postmenopausal osteoporosis]

An estrogen deficiency had lead to the postmenopausal osteoporosis, therefore the hormone replacement therapy (HRT) had accepted for the prevention and treatment of osteoporosis in postmenopausal women in worldwide. But there were some weak points and limits. A half dose HRT is useful for prevent to vaginal bleeding and breast pain, and to be high in the continuation ratio. On the other hand the percent change in lumber bone mineral density from base line in the half dose HRT is lower than the usual dose HRT. Therefore the some combination therapies with half dose HRT were performed. The combination therapies were useful for the patients of Non-responder with HRT. Now we can use the anti-resorptive drugs, Alendoronate and Risedronate, but we think that HRT is Gold-Standard for prevention and treatment in postmenopausal women with osteoporosis, because HRT is useful for the climacteric symptoms and hypercholesterolemia.